In addition, studies in vivo and vitro have found that PPAR-α agonists had therapeutic effects on ischemic retina diseases, especially on diabetic retinopathy, through the downregulation of HIF-1α in endothelial cells (36, 37). This evidence concerns the gene PPARA and retinal ischemia.